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Abstract
Background
Estimates of dengue transmission intensity remain ambiguous. Since the majority of infec-
tions are asymptomatic, surveillance systems substantially underestimate true rates of in-
fection. With advances in the development of novel control measures, obtaining robust
estimates of average dengue transmission intensity is key for assessing both the burden of
disease from dengue and the likely impact of interventions.
Methodology/Principal Findings
The force of infection (λ) and corresponding basic reproduction numbers (R0) for dengue
were estimated from non-serotype (IgG) and serotype-specific (PRNT) age-stratified sero-
prevalence surveys identified from the literature. The majority of R0 estimates ranged from
1–4. Assuming that two heterologous infections result in complete immunity produced up to
two-fold higher estimates of R0 than when tertiary and quaternary infections were included.
λ estimated from IgG data were comparable to the sum of serotype-specific forces of infec-
tion derived from PRNT data, particularly when inter-serotype interactions were allowed for.
Conclusions/Significance
Our analysis highlights the highly heterogeneous nature of dengue transmission. How un-
derlying assumptions about serotype interactions and immunity affect the relationship be-
tween the force of infection and R0 will have implications for control planning. While PRNT
data provides the maximum information, our study shows that even the much cheaper
ELISA-based assays would provide comparable baseline estimates of overall transmission
intensity which will be an important consideration in resource-constrained settings.
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Author Summary
With an estimated 390 million infections each year, dengue imposes a significant global
public health burden. Yet estimates of the intensity of dengue transmission in different set-
tings are still sparse, making it difficult to plan efficient control programs. Since many den-
gue infections have no symptoms, cases reported through hospitals are only a small
proportion of true cases. The authors used seroprevalence surveys which can detect all
past infections to estimate dengue transmission intensity in 22 countries. Estimates de-
rived from data collected using cheaper diagnostic tests were comparable to those making
use of more expensive tests, an important conclusion for surveillance in resource con-
strained countries. We found dengue transmission intensity varied up to 4-fold in endemic
settings, with estimates showing some sensitivity to how many dengue infections were as-
sumed to confer complete immunity.
Introduction
Affecting more than one hundred countries with 2.5 billion people at risk and 50–100 million
infections per year as estimated by the World Health Organisation (WHO), dengue is a global
public health burden [1]. Estimates of global dengue distribution and transmission intensity
(as quantified by either the force of infection—the per capita rate at which susceptible individu-
als acquire infection, or the basic reproduction number, (R0) remain ambiguous [2]. Infection
with any of the four serotypes of dengue virus (DENV-1, 2, 3, and 4) can cause dengue fever
with increased risk of more severe dengue with subsequent heterologous infections. Individuals
develop protective monotypic immunity upon infection with a single serotype. Cross-reactive
immunity is short-lived and the waning of antibodies below a threshold can facilitate antibody-
dependent enhancement (ADE) upon secondary heterologous infection increasing the risk of
more severe outcomes of dengue (such as dengue haemorrhagic fever (DHF) and shock syn-
drome (DSS)) [3–5]. The impact of cross-immunity and tertiary and quaternary infections are
controversial. The estimated duration of short-term cross-protection varies widely from four
months to 9 years [6], 5–12 months [7], 2 years [8], and 1–3 years [9]. However whether this
protects against infection or clinically apparent disease is unknown. Therefore individuals may
still contribute to onward transmission [8,10,11]. Clinically apparent tertiary and quaternary
infections are rarely reported, and cannot be tested for retrospectively [10]. Wikramaratna
et al. showed that tertiary and quaternary infections allows for the high seroprevalence at very
young ages observed in Haiti [12] and Nicaragua [13] better than when assuming complete
protection after two heterologous infections [10]. There are no antiviral therapies available as
yet and disease control is restricted to vector control, community education and the develop-
ment of an effective dengue vaccine.
Recent estimates of the global distribution of dengue and the resulting disease burden have
refined our understanding, but remain controversial [2]. Shepard et al. highlight some of the
difficulties in accurate dengue burden estimation including differences in surveillance systems
leading to underestimation of dengue incidence, the lack of standardized reporting procedures
or diagnostic criteria, and the lack of integration between private and public sectors [14]. Previ-
ous studies have attempted to estimate the burden of dengue and associated economic costs in
South East Asia and South America by calculating expansion factors from systematic literature
reviews, collation of existing data, and population-based cohorts [15–18]. In particular, Bhatt
et al.’s estimate of 390 million dengue infections per year is three times higher than previous of-
ficial WHO estimates, with India accounting for 34% of that total [2]. Motivated by previous
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work on malaria, the Bhatt et al. analysis relied on correlating their geographic niche-modelling
based estimates of dengue presence with burden estimates derived from serological surveys.
While an improvement on previous approaches, the fact that dengue infection induces sero-
type specific neutralising immunity weakens the parallels with malaria, in that the maximum
number of dengue infections an individual can experience is strictly limited (while a person
can experience dozens of malaria infections in their lifetime). Here we argue that obtaining ro-
bust estimates of the geographic variation in average dengue transmission intensity—as quanti-
fied by the basic reproduction number, R0 (the average number of secondary cases resulting
from the introduction of a single infectious individual into a large susceptible population [19]),
of each serotype—is key to improving the reliability of burden estimates. In addition, a quanti-
tative understanding of variation in transmission intensity is essential to assessing the likely
impact of interventions such as vaccine [20,21] or novel vector control measures [22–24].
However, with no standardised diagnostic method, challenging clinical diagnosis (Box 1)
and highly variable surveillance systems, there is no consistent way to estimate global dengue
transmission [25–27]. Dengue transmission is geographically highly heterogeneous, even down
to very fine spatial scales [28]. Most model-based estimates of dengue transmission intensity
and reproduction number have utilised case-notification data, which heavily depend on the
quality of the surveillance system and the health infrastructure of the country in question
[29–36]. Additionally, since the majority of dengue infections generate only mild symptoms,
are asymptomatic, or are clinically diagnosed as a viral infection, even sensitive healthcare-
based surveillance systems substantially underestimate true rates of infection [37,38]. Serologi-
cal data are therefore invaluable in quantifying dengue transmission, in being able to identify
Box 1. Main issues associated with current diagnostic methods.
• Although highly accurate and sensitive, virus isolation and PCR can be time consum-
ing and expensive and relies on sampling (and therefore detection) of
symptomatic cases.
• Routinely used serological methods—IgM and IgG ELISAs—are unable to differentiate
between the 4 dengue serotypes and are affected by cross-reactivity with other flavivi-
ruses (e.g. yellow fever or Japanese encephalitis).
• IgG ELISAs are unable to differentiate between past, recent, and current infection [5].
• IgM ELISAs can be confounded by false positives and are only useful for a limited time
post-infection [86].
• In secondary or later infections, serological diagnosis of the most recent infecting den-
gue serotype is difficult due to the presence of pre-existing cross-neutralising and
cross-reactive antibodies [39,87].
• Serological protocols (e.g. thresholds used to define seropositivity) are not standardised
across laboratories [26].
• Laboratory capacity and general public health infrastructure and surveillance systems
vary widely within and between countries.
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both symptomatic and asymptomatic past infections and thus quantify infection prevalence
and incidence in the population as a whole.
Here we utilise published age-stratified seroprevalence surveys and estimate the force of in-
fection (λ) and corresponding basic reproduction number (R0) for dengue in a variety of set-
tings. Due to the much lower costs, future seroprevalence studies are still likely to depend on
IgM or IgG enzyme-linked immunosorbant assays (ELISAs) rather than the more labour inten-
sive plaque-reduction neutralisation tests (PRNTs). The comparison of estimates derived from
IgG, IE and PRNT data allows us to determine the usefulness of less expensive assays.
Methods
Literature search
We searched MEDLINE, EMBASE, and Web of Knowledge for publications reporting age-
stratified dengue serological surveys. Fig 1 describes the search process and search terms used.
Fig 1. Flowchart describing the literature search process for dengue seroprevalence surveys.
doi:10.1371/journal.pntd.0003719.g001
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Studies published before 1980 were not included in the analysis as we were interested in con-
temporary dengue transmission. Studies reporting age-specific seroprevalence for at least 5 age
groups were included and categorised according to the assay type used. Studies reporting less
than 5 age groups were excluded as these studies tended to have wide age groups where the
mean seroprevalence did not accurately reflect the variability in seroprevalence within that age
group. Data were extracted from published datasets where age-specific seroprevalence was test-
ed by IgG ELISAs, inhibition ELISAs (IEs) or PRNTs. IgG and IE data are both non-serotype
specific and we refer to them interchangeably.
Estimating the force of infection (λ)
In the context of dengue, seroprevalence measures obtained with IgG ELISAs only give an indi-
cation of whether an individual has ‘ever’ been infected and do not differentiate between infect-
ing serotypes or identify the number of past infections.
Since infection with one serotype only provides homologous immunity, a seropositive indi-
vidual may still be susceptible to secondary heterotypic infection [39]. We fitted the single
cross-sectional IgG datasets using a simple catalytic model (model A). The model assumes a
constant infection hazard λ, with infection causing individuals of age a to move from a sero-
negative x(a) to a seropositive z(a) state [19].
Since some datasets appeared to have declining seroprevalence with age, we extended model
A by assuming that protection could decay with age at a rate α (model B). Whenever yearly
cross-sectional IgG data were available from the same location, these data were fitted using a
time-varying catalytic model (model C) which allowed estimation of the periodicity (T), sea-
sonal amplitude (δ) and within-year timing (θ) of dengue outbreaks, and the critical age (Acrit)
and scale (S) at which exposure levels change. See the Supporting Information for full details
(S1 Text).
In order to fit serotype-specific PRNT data, we applied the multi-strain catalytic model
developed by Ferguson et al. [40]. Different model variants were assessed, which explored dif-
ferent assumptions on serotype interactions. Model D1 assumed no serotype-interaction.
Model D2 assumed that cross-protection or enhancement did not vary by serotype. Model D3
assumed that the magnitude of cross-protection or enhancement varied by the primary infec-
tion serotype. Last, model D4 assumed that the magnitude of cross-protection or enhancement
depended on the serotype of the secondary infection.
Moreover, for comparison purposes, we fitted model A to PRNT data, having defined indi-
viduals with PRNT titres below the detection limit for all four dengue serotypes as seronegative
and individuals with at least one PRNT titre over the detection limit as seropositive. Since as-
says differed between surveys, here the detection limit also varied from study to study.
We defined a beta-binomial likelihood for models A—C and a multinomial likelihood for
models D1-D4. Models were fitted to the data using the Metropolis-Hasting Markov Chain
Monte Carlo (M-HMCMC) algorithm using the R Statistical Package (version 3.1.0, R Devel-
opment Core Team, Vienna, Austria) [41]. Full details are given in S1 Text.
Estimating the basic reproduction number R0i
We assumed that dengue is at endemic equilibrium and that the force of infection λ is constant
in time in all cases except model C. Unless otherwise stated, we assumed that all four serotypes
of dengue were in circulation. Since IgG data contain no information on the infecting serotype,
we assumed that the four dengue serotypes are equally transmissible and estimated a single re-
production number applicable to each serotype. For the PRNT data, since we were able to
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estimate serotype-specific forces of infection, we computed strain-specific reproduction num-
bers as described by Ferguson et al. [40].
We computed the reproduction numbers under two different assumptions on the number
of infections required to obtain full protection against infection by any dengue serotype. This
allows us to explore whether tertiary and quaternary infections contribute to transmission sig-
nificantly. Under assumption 1 complete protection is obtained upon quaternary infection (all
four infections contribute equally); whilst under assumption 2 complete protection is reached
upon secondary infection (only primary and secondary infections are infectious). Under as-
sumption 2 we were also able to incorporate cross-immunity leading to inhibition or enhance-
ment of susceptibility to secondary infection. For each model variant other than B, we
computed the serotype-specific basic reproduction number under assumptions 1 and 2. We
only considered model B under assumption 1, as decay of immunity by definition allows an ar-
bitrary number of infections to occur. Full details are given in S1 Text.
Results
We identified 53 studies reporting age-specific seroprevalence from a total of 15,525 potentially
relevant papers (Fig 1). Of these, 38 used non-serotype specific assays including IgG and inhi-
bition ELISAs (IE). Only nine studies used PRNTs and five studies reported results from multi-
ple assays. Excluding studies with less than 5 reported age groups from further analysis left a
total of 30 surveys from 18 countries for IgG data, and 7 studies from 5 countries for PRNT
data. 28 (out of 30) surveys from 17 countries were cross-sectional IgG seroprevalence surveys
from a single year. The remaining 2 (out of 30) surveys were conducted in Nicaragua and com-
bined provided 7 years’ worth of cross-sectional inhibition ELISA (IE) data. Most IgG surveys
identified were conducted in 2000–2010 (23/30), while most PRNT surveys were conducted in
the 1990s (4/7). Although recent serosurveys used commercial diagnostics, many studies used
in-house assays. Tables 1 and 2 summarises the study and demographics of the datasets re-
tained for analysis from the corresponding or closest year. All studies summarised in Table 1
were fitted using model A and B, and model C was also fitted to the two Nicaraguan datasets
(Table 1). Models D1—D4 were fitted to studies summarised in Table 2.
Only an overall force of infection could be estimated from non-serotype specific IgG data.
As expected, estimates of the force of infection varied widely between countries and, to a lesser
extent, within countries (Fig 2A). Southeast Asian countries known to be hyper-endemic for
dengue, such as Vietnam and Thailand, had a higher force of infection compared with most
sites in the Americas [75]. Corresponding estimates of R0i varied according to the assumptions
made regarding host immunity (Fig 2B). Assuming that two heterologous infections are suffi-
cient for complete immunity (Assumption 2) produced up to two-fold higher estimates of R0i
compared to when we assumed that quaternary infections are required for complete immunity
(Assumption 1). However, R0i estimates under these two assumptions converge as the estimat-
ed force of infection decreases.
With age-structured serosurvey data from multiple sequential years (as was available for
Nicaragua, Table S3), it is possible to estimate temporal and age-specific changes in exposure
[13,68] (Fig 3A). We fitted a model (model C) to those data which allowed for the force of in-
fection to vary sinusoidally over time and to change at (fitted) age threshold. We estimated that
exposure increased in individuals over 3.9 years old (95% CI: 2.7–5.4 years), with the estimated
force of infection during the study period (2001–2007) being 0.323 (95% CI: 0.261–0.377)
above 3.9 years and 0.174 (95% CI: 0.118–0.280) below 3.9 years. These estimates represent the
average total force of infection for all four serotypes in circulation. The force of infection was
estimated to vary with a period of 8.8 years (95% CI: 1.3–12.5 years). Resulting estimates of R0i
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(Fig 3B) showed the same dependence on immunity assumptions as the point estimates derived
from single serosurveys (Fig 2), but interestingly showed less temporal variation than the force
of infection estimates (Fig 3A).
PRNT data are serotype-specific, allowing us to estimate the force of infection (λi) and basic
reproduction number (R0i) for each serotype individually (Fig 4). Estimates varied widely be-
tween different surveys, again highlighting the heterogeneity of dengue transmission. Within
the same survey, serotype-specific differences in transmission intensity were apparent, demon-
strating how a certain serotype may be more dominant at any one time point. For example, for
model D2, force of infection estimates for Haiti were 0.046 (95% CI: 0.010–0.179) for DENV-1
but 0.219 (95% CI: 0.088–0.445) for DENV-4.
Comparison of cross-protection or enhancement parameters under different assumptions
allowed us to estimate the probable serotype causing primary and secondary infections. How-
ever, due to the wide credible interval of the estimated parameter, it is difficult to definitively
determine the sequence of infections (Tables S5—S8 in S1 Text). For all datasets, the model fit
improved when we assumed some level of inter-serotype interaction, demonstrating that inter-
serotype interactions play an important role in dengue dynamics.
Interestingly, the serotype-specific estimates of the reproduction number did not scale line-
arly with the estimated values of the force of infection, although the relative order is maintained
i.e. if λ3< λ4 then R03< R04. If one serotype dominates, as was the case in Haiti, changes in the
force of infection of the other non-dominant serotypes marginally affect the estimates of the re-
production number of the non-dominating serotypes.
In order to compare the estimates of dengue force of infection derived from IgG and PRNT
assays, we also analysed the PRNT data ignoring strain-specificity (i.e. treating PRNT data as if
it were IgG data), by categorising individuals as ‘seronegative’ if their PRNT titers were nega-
tive for all serotypes, or seropositive if they tested positive for at least one serotype. We used
the same thresholds for seronegativity used by each source study. The resulting force of infec-
tion estimates generated using model A were consistent with the sum of the individual sero-
type-specific λ estimates obtained from the full PRNT datasets. This consistency was highest
Table 2. Summary of PRNT surveys identified and associated demographics.
Country Author Year Region Age
Range
(Yrs)
N Serotypes^ Population size of
study region
(thousands)
Rural/
Urban
% Aged
<15 yrs
Models
used
Cuba Guzman et al.[69] 1983 Cerro 0–45 1295 2 125.5 Urban 26 A, D1—
D4
Guzman et al.[70] 1997/
98
Santiago 0–95 1151 2 475.6 Urban 17.3 A, D1—
D4
Haiti Halstead et al.[12] 1996/
99
Port au
Prince
6–14 210 4 2000 Urban 43 A, D1—
D4
Indonesia Graham et al.[71] 1995 Yogyakarta 4–10 1837 4 421 Urban 34 A, D1—
D4
Peru Morrison et al.[72] 1999 Iquitos 5–60+ 2524 2 350 Urban 34 A, D1—
D4
Thailand Sangkawibha
et al.[73]
1980 Rayong 0–10 1009 4 53 Suburban 39.4 A, D1—
D4
Thailand Rodriguez-
Barraquer et al.
[74]
2010 Rayong 6–19 1647 4 230 Urban 19.3 A, D1—
D4
^Number of serotypes known to have been in circulation.
doi:10.1371/journal.pntd.0003719.t002
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Fig 2. A) Force of infection and B) correspondingR0i estimates of cross-sectional non-serotypes specific datasets fitted to Model A. Posterior
median and 95% credible intervals shown.
doi:10.1371/journal.pntd.0003719.g002
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when some level of inter-serotype interaction (cross-protection or enhancement) was allowed
for (Fig 5).
Discussion
From a literature review, we selected 39 studies reporting age-structured seroprevalence data
obtained with IgG/IE (31 out of 39) or PRNT (8 out of 39) assays in 22 different locations from
1980 to 2010. From each dataset, we estimated dengue transmission intensity, quantified by
the force of infection (λ) and the basic reproduction numbers (R0i). Overall, our estimates high-
light the highly heterogeneous nature of dengue transmission in both space and time, and by
serotype. Our analysis also highlights how the relationship between the force of infection and
R0i is affected by underlying assumptions about serotype interactions and immunity. The ma-
jority of our estimates of R0i from 22 countries ranged from 1–4 (28 out of 28 and 24 out of 28
Fig 3. Estimated time-varying A) serotype-specific force of infection in individuals under the threshold age and B) R0i derived by fitting Model C to
Nicaraguan data (2001–2007). Posterior median and 95% credible intervals shown.
doi:10.1371/journal.pntd.0003719.g003
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from model A fitted to IgG datasets under assumption 1 and 2 respectively, and 6 out of 7 from
model D2 fitted to the PRNT surveys).
Dengue epidemiology differs between the Americas and Southeast Asia. Severe dengue pre-
dominantly affects children in Southeast Asia in contrast to the Americas where disease more
often manifests in adults as the milder dengue fever [75]. However the changing demographics
in Thailand (lower birth and death rates) have increased the average age of DHF suggesting
that the epidemiology will continue to evolve [36]. However with the cross-sectional data we
use in this study it is difficult to determine whether the higher force of infection in South East
Asia is a reflection of the length of time dengue has been in circulation. The recent Phase III
dengue vaccine trial conducted in several countries in Latin America showed that the forces of
infection are highly heterogeneous across Latin America, with some countries comparable to
South East Asia (Columbia and Honduras) and others having much lower forces of infection
(Mexico and Puerto Rico) [76]. However, multiple cross-sectional surveys or cohort studies
would be needed to estimate how forces of infection by age have changed over time. The low
R0i estimated in the Indian subcontinent is probably due to the lack of datasets from this region
and the spatial heterogeneity of transmission within that large region. The one serosurvey from
India used in our study was conducted in Andaman, an island with a low population density
Fig 4. Serotype-specific estimates of A) force of infection, λi, and B) R0i estimates derived from PRNT datasets fitted to Model D2. Posterior median
and 95% credible intervals shown.
doi:10.1371/journal.pntd.0003719.g004
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where we estimated a very low force of infection. It is likely that the epidemiology of dengue on
Andaman is not representative of dengue epidemiology on the mainland.
Seroprevalence surveys have the benefit of not being affected by surveillance system sensi-
tivity or case reporting rates, but still have several limitations (Box 1) [77,78]. A particular issue
is the wide variation in the assays used between studies (Table 1). Optimally, one would assess
the sensitivity of transmission intensity estimates to factors that varied between assays, such as
the threshold used to define seronegativity. However, such an analysis requires access to the
raw titer data which was not provided in any of the publications we reviewed. Additionally se-
roprevalence surveys sometimes use serum samples collected for a different purpose and there-
fore may not be representative of the population. Six out of the 37 studies used such samples:
from blood banks [44], ante-natal clinics [64], hospitals [55,79,80], or residual samples from a
different study [66]. Use of convenience samples can increase the volume of serological data
produced, but the potential biases such sampling introduces must be taken into account when
analysing such data.
Although we can only calculate a total force of infection across all serotypes from non-sero-
type specific data (such as surveys using IgG ELISA assays), such data are still sufficient for as-
sessing heterogeneity in overall dengue transmission intensity between different populations.
However as demonstrated by the variable serotype specific λi estimated from the PRNT data,
even within the same population, the dominant serotype in circulation changes over time
Fig 5. Total force of infection (λ) estimates (for all 4 serotypes) derived from PRNT datasets fitted to Models A (treating PRNT data as IgG data) and
D1–D4.Models D2–D4 allow for cross-protection between serotypes. Posterior median and 95% credible intervals shown.
doi:10.1371/journal.pntd.0003719.g005
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[8,81,82]. Furthermore, we found that estimates of R0i varied between serotypes, suggesting se-
rotypes (or genotypes) differ in their intrinsic transmissibility [40,74,82]. Therefore the as-
sumption that all serotypes have identical λi required to estimate serotype-specific
transmission intensity from IgG data must be regarded as a crude simplification. However, we
found that non-serotype specific data does yield an estimate of the total force of infection from
all serotypes consistent with the sum of serotype-specific forces of infection able to be derived
from PRNT data, particularly when analysis of the latter allowed for inter-serotype interaction
(cross-protection or enhancement) [8].
It is not possible to disentangle temporal from any age-dependent variation in exposure
from single cross-sectional seroprevalence surveys, requiring broad assumptions to be made
about such variation. Hence, for simplicity, we generally assumed constant transmission inten-
sity over time when analysing single cross-sectional surveys. However, for Nicaragua [13,68],
data from multiple sequentially conducted serosurveys were available, so we were able to esti-
mate time and age-dependent changes in the force of infection. We found evidence of long
term variation in transmission intensity over a timescale of 1–12 years, and that exposure levels
changed with age, with children aged 4 or older having twice the exposure of those under that
age. We suspect that this may be associated with school attendence, with children spending
more time away from home leading to an increase in exposure if the majority of transmission
is occuring outside the domestic environment [72]. This school-cohort effect has also been ob-
served in Sri Lanka, conversely with a decrease in exposure, where Tam et al. estimated an age-
varying force of infection of 0.154 (95% CI: 0.132–0.177) for 0.5–6 year olds and 0.087 (95%
CI: 0.020–0.154) for children aged 6 years and above also demonstrating the existence of differ-
ent transmission environments [63].
Our analysis has a number of additional limitations. First, in translating force of infection
estimates into estimates of R0i we rely on a model which assumes exposure is due to endemic
transmission, meaning all resulting R0i estimates are by definition greater than one. Clearly this
is less appropriate for settings with low seroprevalence such as Texas (USA), where some or all
of the seropositivity detected is due to imported cases rather than local transmission.
Second, estimates of transmission intensity (particularly R0i) are sensitive to assumptions
about cross-protective immunity between serotypes—and most notably the extent to which
tertiary and quaternary infections contribute to transmission. While there is increasing evi-
dence that tertiary and quaternary infections occur [10,82], there is little quantitative data on
the infectiousness of such infections relative to primary and secondary infections. Consistent
with published theory [81], our estimates of R0i were lower when we assumed tertiary and qua-
ternary infections were as infectious as earlier infections (Assumption 1) than when we as-
sumed complete immunity was acquired after secondary infection (Assumption 2). When one
serotype had a very large force of infection relative to the other three serotypes (e.g. Haiti
model 2: DENV-1 at 0.046 (95% CI: 0.010–0.179) compared to DENV-4 at 0.219 (95% CI:
0.088–0.445), then regardless of the value of λi of the remaining serotypes, all R0i estimates
were large and similar to each other. Thus it appears that the value of R0i is dominated by very
large λi and changes in the other three λi play a minimal role. This uncertainty has relevance
for planning interventions [8,11,83], since R0 determines the coverage and effectiveness of vac-
cination or vector control measures required to achieve control of transmission [84]. The re-
cent results from trials of the Sanofi live-attenuated chimeric vaccine [20,21] make this issue
more pressing, since reliable estimates of transmission intensity—and of the health burden due
to dengue—will be important in strategic planning and resource allocation for vaccination in
different contexts.
Third, while PRNT assays are currently the gold standard for routine dengue serotyping,
cross-reactivity means care must be taken when interpreting the results of serosurveys in areas
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where there is co-circulation of different flaviviruses or routine use of yellow fever or Japanese
Encephalitis vaccine [3].
Finally, our literature search highlighted that use of serological surveys as a tool to assess
transmission remains rare for dengue, with publications of outbreak reports and notified case
incidence data being much more common. Generally, published models estimating dengue
transmission risk have therefore used notification data, the reliability of which therefore heavily
depend on the quality of the surveillance system [85]. Gaining a better global picture of the var-
iation in transmission will improve both estimates of the disease burden caused by dengue and
assist in control planning. We would therefore advocate much more widespread and routine
use of serological surveys as a surveillance tool which provides invaluable data for an immunis-
ing infection such as dengue. While PRNT data provides the maximum information, our study
shows that even the much cheaper ELISA-based assays would provide reasonable baseline esti-
mates of overall transmission intensity.
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